3 unchanged sentences
Regardless of the outcome, litigation can have a material adverse effect on us due to defense and settlement costs, diversion of management resources, and other factors.
−Removed: On February 10, 2023, a putative class action lawsuit was filed in the U.S.
−Removed: District Court for the Northern District of California against our company and certain of our officers and current and former members of our board of directors ( Greenhalgh v.
+Added: On April 11, 2023, a putative class action lawsuit was filed in the U.S.
+Added: District Court for the Northern District of California against our company and certain of our officers and current and former members of our board of directors, B ergman v.
Caribou Biosciences, Inc., et al.
−Removed: , Case Number 3:23-cv-00609-VC).
−Removed: The complaint challenges disclosures regarding our company’s business, operations, and prospects, specifically with respect to the alleged durability of CB-010’s therapeutic effect and the product candidate’s clinical and commercial prospects, in alleged violation of Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended.
−Removed: The complaint seeks an unspecified amount of damages on behalf of a putative class of purchasers of our company’s securities during the class period of July 23, 2021, through December 9, 2022, as well as interest and reasonable fees and costs.
−Removed: We believe that this lawsuit is without merit and intend to vigorously defend against it.
+Added: , Case Number 4:23-cv-01742-YGR (“Bergman Case”).
+Added: The Bergman complaint challenges disclosures regarding our company’s business, operations, and prospects, specifically with respect to the alleged durability of CB-010’s therapeutic effect and the product candidate’s clinical and commercial prospects, in alleged violation of Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act.
+Added: On September 18, 2023, plaintiffs filed an amended complaint adding the IPO underwriters as defendants and making substantially the same allegations as the original complaint.
+Added: On November 14, 2023, we filed a motion to dismiss the amended complaint for failure to state a claim.
+Added: Motion to dismiss briefing was completed on February 21, 2024, and oral argument on the motion is scheduled for April 23, 2024.
+Added: We intend to vigorously defend the claims asserted against us.
+Added: On March 22, 2023, a putative class action lawsuit was filed in Superior Court of the State of California for the County of Alameda against our company and certain of our officers and current and former members of our board of directors, Lowry v.
+Added: Caribou Biosciences, Inc., et al.
+Added: , Case Number T23-1084 (“Lowry Case”).
+Added: The Lowry Case challenges disclosures regarding our company’s business, operations, and prospects, specifically with respect to the alleged durability of CB-010’s therapeutic effect and the product candidate’s clinical and commercial prospects, in alleged violation of Sections 11 and 15 of the Securities Act.
+Added: The allegations and claims in the Lowry Case are substantially similar to the Securities Act claims asserted in the Bergman Case.
+Added: On April 26, 2023, we filed a motion to stay the Lowry Case during the pendency of the parallel federal court litigation in the Bergman Case, and, on July 11, 2023, our motion to stay was denied.
+Added: On September 11, 2023, plaintiff filed an amended complaint making substantially the same allegations as the original complaint.
+Added: On November 9, 2023, we filed a motion to dismiss the amended complaint on the grounds that our certification of incorporation mandates that Securities Act claims against us be brought in federal court.
+Added: On February 28, 2024, the court granted our motion to dismiss and ordered the case dismissed.
Mine Safety Disclosures.
Not applicable.
−Removed: Table of Conte n t s
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.